Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Kathryn E. WengelEVP, Chief TO and Risk Officer | Johnson & JohnsonJNJ | Open-market sale | 06/11 | 06/12 | 10,000 sh | $241.15 | $2,411,500 | −8.0% |
Decker Robert J.VP Corporate Controller | Johnson & JohnsonJNJ | Open-market sale | 02/27 | 03/03 | 4,075 sh | $247.87 | $1,010,070.25 | −14.7% |
Timothy SchmidEVP, WW Chair, MedTech | Johnson & JohnsonJNJ | Open-market sale | 02/20 | 02/23 | 1,322 sh | $245.66 | $324,762.52 | −4.9% |
Johnson & JohnsonJNJ | Open-market sale | 02/18 | 02/18 | 22,623 sh2 trades | $244.33avg. | $5,527,505.94 | −45.8% | |
Johnson & JohnsonJNJ | Open-market sale | 02/17 | 02/18 | 53,931 sh3 trades | $243.00avg. | $13,105,233 | −83.5% | |
Johnson & JohnsonJNJ | Open-market sale | 02/17 | 02/18 | 89,654 sh4 trades | $242.80avg. | $21,767,826.99 | −86.5% | |
Johnson & JohnsonJNJ | Open-market sale | 02/13–02/17 | 02/18 | 62,080 sh3 trades | $243.39avg. | $15,109,758.99 | −70.7% | |
Vanessa BroadhurstEVP, Global Corp Affairs | Johnson & JohnsonJNJ | Open-market sale | 02/17 | 02/18 | 6,197 sh | $243.39 | $1,508,287.83 | −21.2% |
CEO and Chairman | Johnson & JohnsonJNJ | Open-market sale | 01/26 | 01/28 | 100,000 sh2 trades | $221.23avg. | $22,122,903.18 | −76.4% |
John G. MorikisDirector | Johnson & JohnsonJNJ | Open-market buy | 25/11/26 | 25/12/01 | 1,250 sh | $206.15 | $257,687.5 | +208.9% |
John C. ReedEVP, Innovative Medicine, R&D | Johnson & JohnsonJNJ | Open-market sale | 25/10/17 | 25/10/20 | 21,721 sh | $192.71 | $4,185,853.91 | −67.1% |
Jennifer L. TaubertEVP, WWC. Innovative Medicine | Johnson & JohnsonJNJ | Open-market sale | 25/09/04 | 25/09/05 | 56,471 sh | $177.81 | $10,041,108.51 | −24.1% |
Joaquin DuatoCEO and Chairman | Johnson & JohnsonJNJ | Open-market sale | 25/08/22 | 25/08/25 | 125,824 sh | $179.21 | $22,548,919.04 | −31.3% |
Wolk Joseph J.Exec VP, CFO | Johnson & JohnsonJNJ | Open-market sale | 25/08/15 | 25/08/18 | 16,820 sh | $176.91 | $2,975,626.2 | −54.6% |
John C. ReedEVP, Innovative Medicine, R&D | Johnson & JohnsonJNJ | Open-market sale | 25/07/17 | 25/07/18 | 19,137 sh | $163.55 | $3,129,856.35 | −64.2% |
Decker Robert J.VP Corporate Controller | Johnson & JohnsonJNJ | Open-market sale | 25/02/25 | 25/02/26 | 6,999 sh | $165.88 | $1,160,994.12 | −25.0% |
Timothy SchmidEVP, WW Chair, MedTech | Johnson & JohnsonJNJ | Open-market sale | 25/02/18 | 25/02/18 | 403 sh | $156.15 | $62,928.45 | −2.6% |
Wolk Joseph J.Exec VP, CFO | Johnson & JohnsonJNJ | Open-market sale | 25/02/07 | 25/02/11 | 13,015 sh | $153.89 | $2,002,878.35 | −100.0% |
Mark A. WeinbergerDirector | Johnson & JohnsonJNJ | Open-market buy | 24/12/12 | 24/12/12 | 1,000 sh | $147.22 | $147,220 | No record |
Decker Robert J.VP Corporate Controller | Johnson & JohnsonJNJ | Open-market sale | 24/08/30 | 24/09/03 | 5,635 sh | $165.06 | $930,113.1 | −22.9% |
